(Yicai) Feb. 28 -- Shares of Healthcare rose after the Chinese maker of Mlily-branded memory foam mattresses said the latest anti-dumping duty investigation in the United States will have a limited impact on its business overseas.

Healthcare's stock price [SHA: 603313] closed up 4.5 percent at CNY10 (USD1.40) after reaching the daily upper limit of 10 percent earlier.

Thin mattresses and other products made by Mlily’s two plants in Spain were excluded from the investigation this time, and their thick mattresses were ruled to pay relatively light import tariffs because they were active respondents, the Nantong-based firm that makes memory foam pillows, electric beds, and dining tables announced yesterday.

Moreover, Mlily’s plant in Thailand, which was ordered to pay almost a 345 percent anti-dumping duty on products exported to the US via Kosovo, no longer delivers mattresses to the States, the company added.

Mlily already has mattress plants in the US so the probe has no big adverse impact on its production and business, the firm added. Besides China factories, Mlily operates plants in South Carolina,  Arizona and several other countries.

The company's mattress business earned CNY3.8 billion (USD527.8 million) in revenue in 2022, almost half of its total, according to the annual report. Nearly 85 percent of the firm's total revenue came from abroad that year.

Editor: Emmi Laine